Skip to main content
. 2016 Apr 8;173(10):1678–1692. doi: 10.1111/bph.13469

Figure 8.

Figure 8

Proposed mechanism of action for DGLβ inhibition via KT109. KT109 inhibits the degradation of diacylglycerol, limiting the formation of 2‐AG, which does not appear to produce functional alterations at either cannabinoid receptor. Decreased 2‐AG, in turn, leads to lower levels of free arachidonic acid, which results in decreased levels of prostaglandins, and subsequent modulation of inflammation and pain.